Will Boehringer-Lilly’s ‘Jardiance’ bring new atmosphere in diabetes treatment market?

Boehringer Ingelheim and Lilly attracted attention as expected to actively enter the SGLT-2 inhibitor market through launching ‘Jardiance(generic name: empagliflozin).’

Boehringer Ingelheim Korea, Lilly Korea and Yuhan Corporation have possessed a diabetes therapy pipeline along with the existing diabetes typ2 therapy, DPP-4 inhibitor ‘Trajenta’ as launching Jardiance this month.

The SGLT-2 i...